CRABP2 and non-small cell lung carcinoma: Moreover, CRABP2, as a diagnostic and targeting biomarker, has been studied in a large number of carcinomas, for instance, the prostate cancer [13], the head and neck tumors [14], the primary retinoblastoma tumors [15], the non-small cell lung cancer [1] and the Wilms tumors[16].